NCT06933524View on ClinicalTrials.gov

Evaluation of Safety and Tolerability of ATB-320 in Participants With Progressive or Metastatic Solid Tumors

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

December 1, 2025

Primary Completion Date

December 1, 2028

Study Completion Date

December 1, 2028

Conditions
Solid Tumors
Interventions
DRUG

ATB-320

IV infusion

Sponsors

Lead Sponsor

Autotelicbio
All Listed Sponsors
lead

Autotelicbio

INDUSTRY